Evidence map›Paper›PMID 33745271›Full record

ArticleACS infectious diseases2021

Synergistic Action of Diclofenac with Endotoxin-Mediated Inflammation Exacerbates Intestinal Injury

Wen Li Kelly Chen, Emily Suter, Hikaru Miyazaki, Jason Velazquez, Douglas A Lauffenburger, Linda G Griffith, Rebecca L Carrier

Open access · greenAbstract read
In one paragraph

Article in ACS infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Frontiers in microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Wen Li Kelly ChenDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
Emily SuterDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
Hikaru MiyazakiDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
Jason VelazquezDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
Douglas A LauffenburgerDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
Linda G GriffithDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.ORCID 0000-0002-1801-5548
Rebecca L CarrierDepartment of Chemical Engineering, Northeastern University, Boston, Massachusetts 02115, United States.ORCID 0000-0003-3002-7098
Massachusetts Institute of Technology · USNortheastern University · US

Funding

GuMI: New In Vitro Platforms to Parse the Human Gut Epithelial-Microbiome-Immune AxisR01EB021908 · NIBIB · NORTHEASTERN UNIVERSITY · PI CARRIER, REBECCA L, GRIFFITH, LINDA G · 2016 to 2020
$5.2M
NIBIB NIH HHS R01 EB021908
6 · The paper itself

Abstract

Intestinal homeostasis is tightly regulated by the orchestrated actions of a multitude of cell types, including enterocytes, goblet cells, and immune cells. Disruption of intestinal barrier function can increase susceptibility to pathogen invasion and destabilize commensal microbial-epithelial-immune interaction, manifesting in various intestinal and systemic pathologies. However, a quantitative understanding of how these cell types communicate and collectively contribute to tissue function in health and disease is lacking. Here, we utilized a human intestinal epithelial-dendritic cell model and multivariate analysis of secreted factors to investigate the cellular crosstalk in response to physiological and/or pathological cues (e.g., endotoxin, nonsteroidal anti-inflammation drug (NSAID)). Specifically, we demonstrated that treatment with diclofenac (DCF), an NSAID commonly used to treat inflammation associated with acute infection and other conditions, globally suppressed cytokine secretion when dosed in isolation. However, the disruption of barrier function induced by DCF allowed for luminal lipopolysaccharide (LPS) translocation and activation of resident immune cells that overrode the anti-inflammatory influence of DCF. DCF-facilitated inflammation in the presence of LPS was in part mediated by upregulation of macrophage migration inhibitory factor (MIF), an important regulator of innate immunity. However, while neutralization of MIF activity normalized inflammation, it did not lead to intestinal healing. Our data suggest that systems-wide suppression of inflammation alone is insufficient to achieve mucosal healing, especially in the presence of DCF, the target of which, the COX-prostaglandin pathway, is central to mucosal homeostasis. Indeed, DCF removal postinjury enabled partial recovery of intestinal epithelium functions, and this recovery phase was associated with upregulation of a subset of cytokines and chemokines, implicating their potential contribution to intestinal healing. The results highlight the utility of an intestinal model capturing immune function, coupled with multivariate analysis, in understanding molecular mechanisms governing response to microbial factors, supporting application in studying host-pathogen interactions.

Indexed as

DiclofenacEndotoxinsEpithelial CellsHumansInflammationIntestinal MucosaDiclofenacEndotoxinsbacterial translocationinflammationleaky gutmacrophage migration inhibitory factor (MIF)NSAIDssmall intestine

Identifiers

PMID33745271
PMCPMC9109718
OpenAlexW3137550468

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.